We further show that increased eIF2α-P is an independent positive prognostic marker for time to tumor progression (TTP) and overall survival (OS) of HER2+ breast cancer patients treated with Trastuzumab-based chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.